Featured Research

from universities, journals, and other organizations

Women May Stop Anticoagulants After Blood Clots, Research Suggests

Date:
August 25, 2008
Source:
Canadian Medical Association Journal
Summary:
Women may safely discontinue oral anticoagulants (blood thinners) after 6 months of treatment following a first unprovoked venous blood clot (thromboembolism) if they have no or one risk factor, concludes a study of 646 participants in a multicenter prospective cohort study.

Women may safely discontinue oral anticoagulants (blood thinners) after 6 months of treatment following a first unprovoked venous blood clot (thromboembolism) if they have no or one risk factor, concludes a study of 646 participants in a multicentre prospective cohort study.

Blood clots are common and a potentially fatal condition. For patients with spontaneous blood clots who stop anticoagulation therapy, the risk of a recurrence in the first year is 5% to 27%, yet there is a risk of major bleeding and fatal hemorrhage while continuing anticoagulants.

"It may be safe for women who have taken oral anticoagulants for 5-7 months after an unprovoked venous thromboembolism to discontinue therapy if they have 0 or 1 of the following:

  1. hyperpigmentation (brown discoloration), edema (swelling) or redness of either leg;
  2. a D-dimer level (blood clotting test) of 250ug/L or more while taking warfarin,
  3. BMI [body mass index] 30kg/m2; and aged 65 years or more,"

conclude Dr. Marc Rodger and coauthors.

The authors caution that "it appears all men are at high risk of recurrence" and further investigation into risk determination needs to be pursued.

In an accompanying commentary, Dr. Clive Kearon states that patient preference for the duration of anticoagulant therapy must be considered in deciding whether to continue or discontinue therapy.


Story Source:

The above story is based on materials provided by Canadian Medical Association Journal. Note: Materials may be edited for content and length.


Cite This Page:

Canadian Medical Association Journal. "Women May Stop Anticoagulants After Blood Clots, Research Suggests." ScienceDaily. ScienceDaily, 25 August 2008. <www.sciencedaily.com/releases/2008/08/080825174953.htm>.
Canadian Medical Association Journal. (2008, August 25). Women May Stop Anticoagulants After Blood Clots, Research Suggests. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2008/08/080825174953.htm
Canadian Medical Association Journal. "Women May Stop Anticoagulants After Blood Clots, Research Suggests." ScienceDaily. www.sciencedaily.com/releases/2008/08/080825174953.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins